Outperformance, underperformance and volatility

The Week in Review #31
IN THE DEPARTED WEEK
NOVEL MIGRAINE DRUGS ARE APPROVED
ELI LILLY AFTER AMGEN AND TEVA
In less than five months, the FDA approved three products belonging to four drug developers – all
targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine headache. The
latest for Eli Lilly (LLY) last week . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.